Appili’s ATI-1701 is intended for infection caused by Francisella tularensis. Credit: Kateryna Kon / Shutterstock.com.

Appili Therapeutics has received an additional $6.6m from the US Air Force Academy (USAFA) to develop the biodefence vaccine candidate ATI-1701.

ATI-1701 is intended to prevent infection caused by Francisella tularensis.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Due to its increased infectiousness, the US National Institutes of Health has categorised Francisella tularensis as a Category A pathogen.

The latest development takes the financial commitments by USAFA for ATI-1701 development to a total of $14m.

In May 2023, the company received $7.3m as part of initial funding for early-stage development and regulatory work on the vaccine candidate. 

See Also:

These activities comprise non-clinical studies, manufacturing and regulatory work for the submission of an investigational new drug (IND) application to the Food and Drug Administration in 2024. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Appili will receive reimbursement for subcontractor and vendor expenditures linked to technical activities.

Appili Therapeutics president and CEO Don Cilla stated: “Being awarded this additional funding commitment from USAFA, in partnership with DTRA, further strengthens Appili’s foundation in biodefence and enables us to scale up our efforts to develop an urgently needed vaccine for this serious bioterrorism threat. 

“This level of funding commitment should further support nonclinical, manufacturing and regulatory activities for ATI-1701, and should enable us to continue to advance this programme towards an IND.”

In May 2023, the company obtained a US patent for ATI-1501, a liquid oral reformulation of metronidazole.